Drug profile · INN
nelarabine
ATRIANCE
nelarabine (ATRIANCE) is a dna inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — nelarabine
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
nelarabine (ATRIANCE) is a dna inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA inhibitor
Primary target: DNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Related & competitor drugs
Frequently asked questions
What is nelarabine?
nelarabine (ATRIANCE) is a dna inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for nelarabine?
ATRIANCE is a marketed brand name for nelarabine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of nelarabine?
nelarabine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.